Here's why the Volpara (ASX:VHT) share price is up 6% today

The Volpara (ASX: VHT) share price is gaining today after the company released its quarterly results. Let's take a look.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Volpara Health Technologies Ltd (ASX: VHT) shares are gaining today after the company released its quarterly results. At the time of writing, the Volpara share price is up 6.25%, trading at $1.36 apiece.

Volpara is a health technology software company, providing an integrated breast care platform to deliver personalised breast care. Let's take a closer look at the New Zealand-based company's latest results.

Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares

Image source: Getty Images

Fourth-quarter results

The company released its results for the fourth quarter of the 2021 financial year this morning, garnering a positive reaction from investors.

Good news from the company included a record cash income from customer receipts, equalling NZ$5.4 million. That figure represents a 15% increase compared to the fourth quarter of 2020.

The company's subscription-based receipts were also up, raking in NS$18.3 million – a 39% year on year increase.

Volpara also announced increases in its unaudited cash receipts for the full year ending 31 March 2021, up 20% year on year.

Its net operating cash outflow was better than the company's internal forecasting, and it ended the quarter with $32.2 million cash in the bank.

Volpara's earnings before interest, tax, depreciation and amortisation (EBITDA) came in at a loss of NZ$3,432,000.

Today is the second time Volpara's share price has reacted positively to its results for this quarter. On 20 April, the Volpara released a business update on the fourth quarter, which also saw its share price rise.

Unfortunately, its gains didn't hold that day, and the Volpara share price ended the session trading 4.2% lower than the previous close.

Commentary from management

Volpara CEO Dr Ralph Highnam commented on the results, saying:

Our achievements in [the 2021 financial year] are a powerful endorsement of what we stand for as a company and the strength and commitment of our industry to keep saving families from cancer, no matter what else is going on.

We look forward to continuing to accelerate out of COVID-19 in [the 2022 financial year].

Volpara share price snapshot

Currently, the Volpara share price is down 3% year to date, although it's up 8% over the last 12 months.

The company has a market capitalisation of around $321 million, with approximately 251 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends VOLPARA FPO NZ. The Motley Fool Australia has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A cool white-bearded man holds his hand up signalling you should halt.
Healthcare Shares

ASX 300 cannabis stock Incannex suspended ahead of 'material update'

The Incannex share price is frozen at 14 cents for now.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX All Ords stock is rocketing 27% on a new FDA approval

Rett Syndrome has finally got an approved treatment.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Buy these excellent ASX 200 healthcare shares: Goldman Sachs

Goldman has spoken very positively about these healthcare shares this week.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Guess which ASX biotech stock just rocketed 29% on big FDA news

The ASX healthcare share is attracting investor interest following FDA approval for its targeted cancer therapy compound.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares while they're under $300?

Can investors make a healthy return with this biotech?

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Mesoblast share price rockets 23% on FDA news

Mesoblast has received some good news for the US FDA this morning.

Read more »

A young woman wearing a blue blouse with white polkadots holds her phone up with an intrigued and happy look on her face as she reads some news.
Healthcare Shares

Owners of this ASX 200 share are soon going to receive a bigger dividend

Investors in this healthcare company are about to get a healthy cash boost.

Read more »

an older couple look happy as they sit at a laptop computer in their home.
Healthcare Shares

Hoping to collect the latest CSL dividend? Here's how

The next CSL dividend is fast approaching.

Read more »